Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Q2 2025 Earnings Presentation

25 slides from Avadel Pharmaceuticals's earnings presentation, Aug 7, 2025

  1. Slide 1: Avadel Pharmaceuticals plc

    AVADEL Pharmaceuticals plc (NASDAQ: AVDL)

  2. Slide 2: Safe Harbor Statements

    Safe Harbor Statements This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, obje

  3. Slide 3: A Biopharmaceutical Company Focused on Transforming Medicines to Transform Lives

    A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES 3

  4. Slide 4: Strong and Experienced Management Team and Board with Proven Success

    Strong and Experienced Management Team and Board Of Directors with Proven Success Recognizing and Unlocking Value Delivered a once-nightly treatment option for patients with narcolepsy, a Clinical drug class that hasn’t experienced significant medical innovation in over 20 years Navigated two approv

  5. Slide 5: AVDL at a glance

    >$300M Revenue Since Launch* Corporate Headquarters Publicly traded on Dublin, Ireland NASDAQ since 1996 : AVDL ~3,100 Patients on therapy* St. Louis, US Operations Missouri Wholly-owned pipeline with expansion Management team with extensive opportunities commercial experience in rare and 31 Orange

  6. Slide 6: LUMRYZ development and approval timeline

    July 2024 June 2023 First patient dosed in Phase 3 LUMRYZ REVITALYZ trial assessing LUMRYZ for (sodium oxybate) the treatment of idiopathic 2018-2019 2021-2022 Extended-Release hypersomnia Focused development Initiated and completed Oral Suspension efforts on LUMRYZ for RESTORE open-label launched t

  7. Slide 7: Advancing Innovative and Transformative Sleep Medicine Pipeline

    Advancing Innovative and Transformative Sleep Medicine Pipeline REGULATORY PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL MAJOR MILESTONES REVIEW Narcolepsy – Excessive Daytime Received FDA approval Sleepiness (EDS) and ODE in May 2023; and/or Cataplexy in launched in June 2023 Ad

  8. Slide 8: Oxybates are the only class of drugs that addresses all 3 symptoms of narcolepsy

    In narcolepsy, the body cannot separate wake and sleep – they blend together. Key symptoms include the following: 1. Excessive daytime sleepiness (EDS), pathological sleepiness during the day. 2. Cataplexy, the sudden onset of weak or paralyzed muscles, usually brought on by strong emotions or certa

  9. Slide 9: LUMRYZ's Market Opportunity in Narcolepsy is >50K Patients

    LUMRYZ's Market Opportunity in Narcolepsy is >50K Patients >14K patients currently treated Over 50K oxybate-eligible >14,000 patients with first-generation patients with narcolepsy oxybates 25,000+ >50,000 >15K patients who discontinued first- Oxybate market potential patients patients of +$5B1 gene

  10. Slide 10: >25,000 Eligible patients have never started an oxybate

    Of eligible patients state middle-of-the-night ~40% dosing is one of the main reasons they have not tried a twice-nightly oxybate >25,000 Eligible patients have never started an oxybate Of providers who have never prescribed an oxybate agree that middle-of-the-night dosing >90% is a challenge for pa

  11. Slide 11: ~65% of Patients with Narcolepsy Experience Poor, Fragmented Sleep

    ~65% of Patients with Narcolepsy Experience Poor, Fragmented Sleep in Addition to their Daytime Symptoms, Despite Getting Adequate Rest SLEEP CON SOLIDATION ASLEEP AWAKE ASLEEP AWAKE NORMAL NARCOLEPSY 11

  12. Slide 12: Once-Nightly Dosing is a Significant Differentiator Vs. First-Generation Oxybates

    Once-Nightly Dosing is a Significant Differentiator Vs. First-Generation Oxybates 80 Maximum concentration 70 of LUMRYZ GHB Concentration, µg/mL (mean ± SE) 60 Granted Orphan Drug Exclusivity in 50 adults and pediatric patients seven 40 years of age and older with narcolepsy 30 based on FDA’s determ

  13. Slide 13: Launch to Date

    Launch to Date1 >$300 Net revenue ($M) ~3,100 Patients on therapy Since its launch in June 2023, LUMRYZ has seen Of patients on therapy consistent patient uptake are switch patients >50% from first-generation oxybates 1) Figures as of June 30, 2025 13

  14. Slide 14: LUMRYZ Market Position and 2025 Key Launch Priorities

    LUMRYZ Market Position and 2025 Key Launch Priorities

  15. Slide 15: 2025 Priorities Focused on Enrollment and Pull Through Accelerators

    2 Years Post-launch, LUMRYZ Has Gained a Strong Market Position with Significant Momentum And Opportunities To Accelerate Growth Broad and Growing Writer Base Adopting across all patient types – switch, new to oxybate, previously discontinued oxybate Executing Market-Leading Office and Patient Servi

  16. Slide 16: Increasing Investments in Salesforce, Direct-to-Patient and HCP Marketing

    Increasing Investments in Salesforce, Direct-to-Patient and HCP Marketing and Field Reimbursement Teams to Drive Patient Uptake and Market Expansion Leverage LUMRYZ’s value Achieve market leadership Increase reimbursed proposition to grow in the new to brand patient mix to 80% and switch and total p

  17. Slide 17: Targeted and Early Intervention is Crucial in Addressing Patient Persistency

    Targeted and Early Intervention is Crucial in Addressing the Historic Challenges of Patient Persistency Seen with Oxybates Doubled nursing team at our patient services center allowing for more frequent/tailored patient Improving LUMRYZ interventions Persistency Can Have an Increased our field suppor

  18. Slide 18: >90% of Commercial Lives Covered; Contracts with All Three PBM-Owned GPOs

    Of Commercial Lives Covered; >90% Contracts in Place with All Three PBM-Owned GPOs Essential access and affordability programs ✓ $0 commercial copay program ✓ Patient assistance program ✓ Temporary assistance program All patients have access Personalized support for patients and offices to patient s

  19. Slide 19: LUMRYZ Expansion Opportunities

    LUMRYZ Expansion Opportunities

  20. Slide 20: Idiopathic hypersomnia opportunity and REVITALYZ Phase 3 trial

    Idiopathic hypersomnia (IH) is a rare sleep disorder characterized by excessive daytime sleepiness (EDS) not attributable to any other ~11% treated medical conditions; 42,000 patients with the only FDA diagnosed with IH in US approved oxybate treatment Initiated REVITALYZ Phase 3 trial to evaluate t

  21. Slide 21: A Leader in the Sleep Space With Substantial Growth Opportunities

    A Leader in the Sleep Space With Substantial Growth Opportunities Meeting Unmet Needs in Narcolepsy 94%1 of patients prefer LUMRYZ over first-generation oxybates due to once at night dosing; awarded Orphan Drug Exclusivity for major contribution to patient care Opportunity For Growth In Narcolepsy $

  22. Slide 22: Financials

    Financials

  23. Slide 23: Financial Summary

    Financial Summary1 Q2 YTD ($ in millions) 2025 2024 2025 2024 Product Revenue $68.1 $41.5 $120.6 $68.7 Operating Expenses $52.9 $51.5 $102.8 $103.1 Operating Income $8.9 ($12.7) $5.9 ($38.8) (Loss) Cash, Cash Equivalents & Marketable $81.5 $71.4 $81.5 $71.4 Securities 1 – Refer to Forms 10-Q for the

  24. Slide 24: GAAP vs. Non-GAAP Reconciliation

    GAAP vs. Non-GAAP Reconciliation Q2 YTD ($ in millions) 2025 2024 2025 2024 GAAP Operating Income (Loss) $8.9 ($12.7) $5.9 ($38.8) Stock Based Compensation $5.3 $5.5 $9.5 $10.9 Depreciation & Amortization 1 $0.8 $1.0 $1.5 $2.1 Transaction Costs 2 $- $5.0 $- $5.5 Non-GAAP Operating Income (Loss) $15.

  25. Slide 25: Join us on our transformational journey

    Join us on our transformational journey 25

Avadel Pharmaceuticals — Q2 2025 Earnings Presentation on 6ix